Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend

Century Therapeutics

13/05/2026 13:10

Overview

US biotech firm's Q1 net loss narrowed, beating analyst expectations

Q1 operating loss also beat analyst expectations

Company ended Q1 with $217 mln in cash, projects runway into Q1 2029

Outlook

Century projects cash runway into 1Q 2029

Result Drivers

LOWER R&D SPENDING - Co said Q1 R&D expenses fell mainly due to reduced personnel and lower clinical trial spending

LOWER G&A EXPENSES - Q1 G&A expenses decreased from prior year period

Company press release: ID:nGNX63q5G4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$21.65 mln
-$23.94 mln (3 Analysts)
Q1 Operating Income
Beat
-$23.68 mln
-$25.97 mln (3 Analysts)
Q1 Basic EPS
-$0.11
Q1 Operating Expenses
$23.68 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Century Therapeutics Inc is $4.50, about 96.5% above its May 12 closing price of $2.29

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)